One company leads in gene-editing approvals, while the other targets surging demand in metabolic treatments. Here’s how their ...
In a study published in Science Translational Medicine, a team of researchers led by Dr. Wang Yu from the Shenzhen Institutes ...
FDA expands Casgevy CRISPR gene therapy to children aged 2+ with sickle cell disease and beta thalassemia, enabling earlier ...
Morning Overview on MSN
The first baby treated with a custom CRISPR therapy is thriving a year later
One year after receiving three doses of a custom-built CRISPR base-editing therapy at Children’s Hospital of Philadelphia, ...
In late June 2026, CRISPR Therapeutics AG was added to several Russell growth indexes, including the Russell 2000 Growth, ...
Recent data published in NEJM demonstrates that CRISPR gene-editing therapy achieves complete clinical efficacy endpoints in ...
A handful of start-up firms are testing therapies that target specific epigenetic markers to treat everything from high ...
CRISPR Therapeutics wins FDA pediatric approval for Casgevy, boosting market potential and pipeline upside despite slow uptake. Click here to read more.
Casgevy sickle cell gene therapy is now FDA-approved for children as young as two, opening access for 5,500 more U.S. kids.
A handful of start-up firms are testing therapies that target specific epigenetic markers to treat everything from high ...
The company seems to be doing everything it's supposed to be doing; the stock just isn't responding.
In a rapidly changing climate landscape, the plants we rely on for food, textiles and more face a multitude of challenges, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results